Cargando…

Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study

BACKGROUND: Patients with irritable bowel syndrome (IBS) seen by a gastroenterologist often utilize medications that may alter intestinal homeostasis. The question arises whether exposure to these drugs is associated with the development of IBS symptoms. Aim of this study was therefore to assess the...

Descripción completa

Detalles Bibliográficos
Autores principales: Keszthelyi, Daniel, Dackus, Gwen H, Masclee, Gwen M, Kruimel, Joanna W, Masclee, Ad AM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482574/
https://www.ncbi.nlm.nih.gov/pubmed/22950677
http://dx.doi.org/10.1186/1471-230X-12-121
_version_ 1782247882559062016
author Keszthelyi, Daniel
Dackus, Gwen H
Masclee, Gwen M
Kruimel, Joanna W
Masclee, Ad AM
author_facet Keszthelyi, Daniel
Dackus, Gwen H
Masclee, Gwen M
Kruimel, Joanna W
Masclee, Ad AM
author_sort Keszthelyi, Daniel
collection PubMed
description BACKGROUND: Patients with irritable bowel syndrome (IBS) seen by a gastroenterologist often utilize medications that may alter intestinal homeostasis. The question arises whether exposure to these drugs is associated with the development of IBS symptoms. Aim of this study was therefore to assess the use of PPIs and NSAIDs in patients with IBS versus controls. METHODS: Cases of IBS from the last 5 years were reviewed. All patients having had at least one prescription for a particular drug (PPIs, NSAIDs, SSRIs, diuretics, ACE inhibitors) in the 6 months prior to the time of initial symptom onset were considered exposed. The control group consisted of individuals randomly selected from the general population. RESULTS: 287 cases of IBS were retrieved for analysis together with 287 age and sex-matched controls. Exposure to PPIs and NSAIDs was significantly higher in IBS patients, whereas no association between ACE inhibitor use and IBS was found. PPIs were not significantly associated when excluding patients with gastrointestinal reflux disease or functional dyspepsia. Exposure to SSRIs was also positively associated with IBS, but only when patients with psychiatric comorbidity were included in the analyses. CONCLUSIONS: Medications that may alter intestinal homeostasis such as NSAIDs and PPIs were more frequently used in IBS patients compared to controls. This association might be relevant for everyday clinical practice, but it is remains to be elucidated whether this association is of etiological nature.
format Online
Article
Text
id pubmed-3482574
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34825742012-10-29 Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study Keszthelyi, Daniel Dackus, Gwen H Masclee, Gwen M Kruimel, Joanna W Masclee, Ad AM BMC Gastroenterol Research Article BACKGROUND: Patients with irritable bowel syndrome (IBS) seen by a gastroenterologist often utilize medications that may alter intestinal homeostasis. The question arises whether exposure to these drugs is associated with the development of IBS symptoms. Aim of this study was therefore to assess the use of PPIs and NSAIDs in patients with IBS versus controls. METHODS: Cases of IBS from the last 5 years were reviewed. All patients having had at least one prescription for a particular drug (PPIs, NSAIDs, SSRIs, diuretics, ACE inhibitors) in the 6 months prior to the time of initial symptom onset were considered exposed. The control group consisted of individuals randomly selected from the general population. RESULTS: 287 cases of IBS were retrieved for analysis together with 287 age and sex-matched controls. Exposure to PPIs and NSAIDs was significantly higher in IBS patients, whereas no association between ACE inhibitor use and IBS was found. PPIs were not significantly associated when excluding patients with gastrointestinal reflux disease or functional dyspepsia. Exposure to SSRIs was also positively associated with IBS, but only when patients with psychiatric comorbidity were included in the analyses. CONCLUSIONS: Medications that may alter intestinal homeostasis such as NSAIDs and PPIs were more frequently used in IBS patients compared to controls. This association might be relevant for everyday clinical practice, but it is remains to be elucidated whether this association is of etiological nature. BioMed Central 2012-09-05 /pmc/articles/PMC3482574/ /pubmed/22950677 http://dx.doi.org/10.1186/1471-230X-12-121 Text en Copyright ©2012 Keszthelyi et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Keszthelyi, Daniel
Dackus, Gwen H
Masclee, Gwen M
Kruimel, Joanna W
Masclee, Ad AM
Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study
title Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study
title_full Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study
title_fullStr Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study
title_full_unstemmed Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study
title_short Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study
title_sort increased proton pump inhibitor and nsaid exposure in irritable bowel syndrome: results from a case-control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482574/
https://www.ncbi.nlm.nih.gov/pubmed/22950677
http://dx.doi.org/10.1186/1471-230X-12-121
work_keys_str_mv AT keszthelyidaniel increasedprotonpumpinhibitorandnsaidexposureinirritablebowelsyndromeresultsfromacasecontrolstudy
AT dackusgwenh increasedprotonpumpinhibitorandnsaidexposureinirritablebowelsyndromeresultsfromacasecontrolstudy
AT mascleegwenm increasedprotonpumpinhibitorandnsaidexposureinirritablebowelsyndromeresultsfromacasecontrolstudy
AT kruimeljoannaw increasedprotonpumpinhibitorandnsaidexposureinirritablebowelsyndromeresultsfromacasecontrolstudy
AT mascleeadam increasedprotonpumpinhibitorandnsaidexposureinirritablebowelsyndromeresultsfromacasecontrolstudy